full timeline
Malaria vaccine research and development
A genetically engineered whole-parasite vaccine safely blocked infection in 13 of 15 volunteers exposed to a highly divergent strain of the disease.
Follow Malaria vaccine research and development in the Factlen app and get an alert when there is news. Get the app
Share this story
Latest report
Whole-Parasite PfSPZ-LARC2 Malaria Vaccine Achieves 87 Percent Efficacy in Trial
A genetically engineered whole-parasite vaccine safely blocked infection in 13 of 15 volunteers exposed to a highly divergent strain of the disease.
- The genetically attenuated PfSPZ-LARC2 malaria vaccine demonstrated 87 percent efficacy in a Phase 1 controlled human challenge trial in Seattle.
- Only two of 15 vaccinated volunteers developed an infection after deliberate exposure to live parasites, compared to all seven placebo recipients.
- The vaccine utilizes a West African parasite strain with two genetic deletions that safely halt its growth in the liver, preventing clinical illness.
- The trial successfully tested cross-strain immunity by exposing participants to a highly divergent Brazilian malaria strain 12 to 16 weeks after vaccination.
A genetically attenuated whole-parasite malaria vaccine has demonstrated 87 percent efficacy in preventing infection during a Phase 1 controlled human challenge trial. Investigators reported the results on November 20, 2026, at the annual meeting of the American Society of Tropical Medicine and Hygiene in Washington, D.C.[2][4]
The investigational candidate, designated the Sanaria PfSPZ-LARC2 vaccine, safely blocked the Plasmodium falciparum parasite in the vast majority of vaccinated volunteers. The trial deliberately exposed participants to live malaria parasites under carefully controlled clinical conditions in Seattle to directly measure the formulation's protective capacity.[4][5]
Within the study cohort, 22 human participants underwent the controlled malaria challenge. Among the group, 15 individuals received the active PfSPZ-LARC2 vaccine formulation, while seven participants received a saline placebo preparation.[2][5]
Following the deliberate exposure to viable parasites, all seven placebo recipients developed clinical malaria infections. In stark contrast, only two of the 15 vaccinated individuals contracted an infection, establishing the 87 percent protective efficacy rate under the stringent challenge conditions.[4][5]
Researchers promptly and safely treated all infected individuals using established antimalarial protocols. The trial's safety monitoring committee reported that the vaccine was safe and well tolerated by the study participants, with no severe adverse events linked to the genetic attenuation.[1][3]
Engineering a halted parasite
The PfSPZ-LARC2 formulation functions as a live-attenuated whole-parasite vaccine, a complex biological approach that introduces the human immune system to a comprehensive assortment of thousands of parasite proteins. The parasite initially develops similarly to a conventional malaria pathogen.[3][5]
To prevent the vaccine from causing actual illness, scientists engineered the underlying parasite strain with two specific genetic deletions. By removing the Mei2 and LINUP genes, researchers ensured the parasite cannot complete its lifecycle and transition into the pathogenic blood stage.[4][6]
These precise genetic deletions allow the parasite to grow normally and replicate up to 50,000 times during its initial liver stage, which massively amplifies the immune stimulus. However, the modifications safely halt its development before it can rupture into the bloodstream and trigger symptomatic malaria.[2][4]
The attenuated PfLARC2 strain was originally created in the laboratory of Dr. Stefan Kappe at Seattle Children's Research Institute. Kappe developed the strain alongside co-inventors Dr. Debashree Goswami and Dr. Ashley Vaughan before it advanced to clinical-stage manufacturing.[2][5]
"It is truly rewarding to see that this vaccine is safe and how well it has protected against challenge with a highly divergent malaria strain in the Seattle trial," Kappe noted following the release of the efficacy data.[2]
Maryland-based biotechnology firm Sanaria Inc. led the subsequent clinical-stage development, manufacturing, and commercial advancement of the formulation. The company specializes in producing whole-parasite malaria vaccines that require cryogenic preservation and direct venous inoculation.[2][5]
Testing cross-strain immunity
The Phase 1 trial was conducted by UW Medicine and its partners within the Infectious Diseases Clinical Research Consortium. The study was sponsored by the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health, with participant enrollment beginning in the summer of 2025.[1][6]
Investigators deliberately introduced a long interval between the final immunization and the challenge to test the durability of the immune response. Participants were exposed to the live parasites between 12 and 16 weeks after receiving their final scheduled vaccine dose.[4][5]
To evaluate whether the vaccine could provide broad protection, the research team used a challenge strain originating from Brazil. The vaccine itself, however, is derived from a distinct West African parasite isolate.[2][3]
This geographic divergence is critical because the Plasmodium falciparum parasite exhibits significant genetic variation globally. A viable commercial vaccine must protect populations regardless of the specific local strain circulating in their region.[2][4]
Dr. Sean C. Murphy, a co-principal investigator for the trial, emphasized the technological milestones that enabled the study. He noted that the trial relied on decades of foundational research into the biology of Plasmodium parasites, alongside the rapid maturation of precise genetic engineering tools.[2]
"This study was made possible by the culmination of decades' worth of research on the biology of Plasmodium parasites and the maturation of genetic engineering technologies that allowed scientists to modify the parasite genome to make it safe for use in humans," Murphy said.[2]
A new chapter in malaria prevention
Malaria transmission remains a profound global health crisis, accounting for an estimated 263 million cases worldwide in 2023. The mosquito-borne disease resulted in approximately 597,000 reported deaths, primarily affecting young children in sub-Saharan Africa.[5][6]
The World Health Organization has urgently called for next-generation malaria vaccines capable of achieving greater than 90 percent efficacy against Plasmodium falciparum infection. Health authorities view this high threshold as absolutely necessary to drive toward the eventual global elimination of the disease.[6]
Earlier iterations of whole-parasite vaccines relied on co-administering antimalarial drugs, such as chloroquine, to kill the parasite after inoculation. The genetic attenuation of PfSPZ-LARC2 removes the safety risks and logistical hurdles associated with drug-dependent attenuation.[4]
The trial relied heavily on Seattle's established human challenge infrastructure, which has supported malaria research since 2011. Dr. Jim Kublin of the Fred Hutch Cancer Center noted that the model provides rapid insights into new drugs and vaccines using a dedicated testing facility and an altruistic volunteer population.[3][4]
Dr. R. Scott McClelland, who led clinical site operations at Harborview Medical Center's Virology Research Clinic, highlighted the operational demands of the stringent challenge model.[1][4]
"It takes a strong and well-coordinated clinical trial team with excellent laboratory resources and with highly engaged and committed research participants to carry out these kind of studies," McClelland said.[4]
Highly sensitive molecular assaying for the trial was provided by the UW Medicine Malaria Molecular Diagnostic Laboratory. This rigorous monitoring process ensured that any breakthrough infections were detected and treated before participants developed severe symptoms.[4][6]
Next steps for clinical development
Following the successful Seattle challenge, the research consortium intends to advance the vaccine candidate into broader Phase 2 testing. Researchers emphasize that larger field trials in malaria-endemic nations, including Burkina Faso and Mali, are still needed before the formulation can reach the populations most at risk.[4][7]
These upcoming field studies will determine how the vaccine's protective efficacy in malaria-naïve adults translates to young children who face repeated, natural exposure. The highest priority remains confirming that the genetic attenuation holds up safely in diverse, highly exposed populations.[2][7]
By demonstrating that a genetically arrested parasite can safely induce robust, cross-strain protection, the PfSPZ-LARC2 trial establishes a verifiable clinical foundation. Investigators plan to continue utilizing the Seattle challenge resources to refine the dosing and administration protocols for future iterations.[2][4]
Sources
- [1]UW Medicine — Malaria vaccine shows 87% efficacy in clinical trial Read on UW Medicine →
- [2]News-Medical — Genetically engineered malaria vaccine demonstrates 87% efficacy in phase 1 trial Read on News-Medical →
- [3]UA.News — In the US, a malaria vaccine showed 87% efficacy in a trial — News-Medical Read on UA.News →
- [4]MedPath — Genetically Attenuated Whole-Parasite Malaria Vaccine PfSPZ-LARC2 Shows 87% Efficacy in Phase 1 Challenge Trial Read on MedPath →
- [5]Bioengineer.org — Genetically Attenuated Malaria Vaccine Demonstrates 87 Percent Efficacy in Early Clinical Trial Read on Bioengineer.org →
- [6]Infectious Diseases Clinical Research Consortium — IDCRC launches Phase 1 clinical trial for innovative malaria vaccine Read on Infectious Diseases Clinical Research Consortium →
- [7]Science Made Simple — Genetically Weakened Malaria Vaccine Blocks 87% of Infections Read on Science Made Simple →
What to watch
- A next-generation, whole-parasite malaria vaccine based on the AV27 hybrid parasite is entering clinical trials.
Charts, maps and images
Timeline
November 2026
Whole-Parasite PfSPZ-LARC2 Malaria Vaccine Achieves 87 Percent Efficacy in Trial
Scientists Breed Pan-African Hybrid Parasite to Advance Universal Malaria Vaccine
How the story developed
On November 13, 2026, researchers successfully mated East and West African malaria strains inside mosquitoes. This process created a high-yield, highly infective hybrid parasite known as AV27.
The AV27 strain was developed to solve key limitations of earlier vaccine candidates. It combines high manufacturing yields with aggressive liver infectivity.
The hybrid parasite retains approximately 90 percent of the immune-targeting peptides from both of its parent strains. This retention is designed to offer broader protection against the disease.
The resulting AV27 parasite will serve as the biological engine and foundation for a next-generation, whole-parasite malaria vaccine candidate.

